Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency.

Rubinstein E, Stolz LE, Sheffer AL, Stevens C, Bousvaros A.

BMC Gastroenterol. 2014 Apr 9;14:71. doi: 10.1186/1471-230X-14-71.

2.

Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.

Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE.

Ann Allergy Asthma Immunol. 2013 Mar;110(3):184-188.e2. doi: 10.1016/j.anai.2012.12.007. Epub 2013 Jan 5.

PMID:
23548529
3.

Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.

Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA.

Ann Allergy Asthma Immunol. 2013 Mar;110(3):168-72. doi: 10.1016/j.anai.2012.12.004. Epub 2013 Jan 8.

PMID:
23548526
4.

Use of ecallantide in pediatric hereditary angioedema.

MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R.

Pediatrics. 2013 Aug;132(2):e490-7. doi: 10.1542/peds.2013-0646. Epub 2013 Jul 22.

5.

Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.

Banta E, Horn P, Craig TJ.

Allergy Asthma Proc. 2011 Jul-Aug;32(4):319-24. doi: 10.2500/aap.2011.32.3440.

PMID:
21781409
6.

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.

Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE.

Allergy Asthma Proc. 2013 Mar-Apr;34(2):155-61. doi: 10.2500/aap.2013.34.3653. Erratum in: Allergy Asthma Proc. 2013 May-Jun;34(3):291.

PMID:
23484891
7.

Ecallantide: in acute hereditary angioedema.

Garnock-Jones KP.

Drugs. 2010 Jul 30;70(11):1423-31. doi: 10.2165/11205850-000000000-00000. Review.

PMID:
20614949
8.

Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks.

Prematta MJ, Bewtra AK, Levy RJ, Wasserman RL, Jacobson KW, Machnig T, Craig TJ.

Adv Ther. 2012 Oct;29(10):913-22. doi: 10.1007/s12325-012-0053-5. Epub 2012 Sep 27.

PMID:
23054691
9.

Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.

MacGinnitie AJ, Campion M, Stolz LE, Pullman WE.

Allergy Asthma Proc. 2012 Mar-Apr;33(2):178-85. doi: 10.2500/aap.2012.33.3528.

PMID:
22525395
10.

Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.

Bernstein JA, Shea EP, Koester J, Iarrobino R, Pullman WE.

Allergy. 2012 Sep;67(9):1173-80. doi: 10.1111/j.1398-9995.2012.02864.x. Epub 2012 Jul 5.

11.

Management of acute attacks of hereditary angioedema: role of ecallantide.

Duffey H, Firszt R.

J Blood Med. 2015 Apr 16;6:115-23. doi: 10.2147/JBM.S66825. eCollection 2015. Review.

12.

Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency.

Patel NS, Fung SM, Zanichelli A, Cicardi M, Cohn JR.

Allergy Asthma Proc. 2013 Jan-Feb;34(1):72-7. doi: 10.2500/aap.2013.34.3620.

PMID:
23406939
13.

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.

Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T.

J Allergy Clin Immunol. 2007 Aug;120(2):416-22. Epub 2007 Jun 7.

PMID:
17559913
14.

Clinical Pattern and Acute and Long-term Management of Hereditary Angioedema Due to C1-Esterase Inhibitor Deficiency.

Gómez-Traseira C, Pérez-Fernández E, López-Serrano MC, García-Ara MC, Pedrosa M, López-Trascasa M, Caballero T.

J Investig Allergol Clin Immunol. 2015;25(5):358-64.

15.

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.

Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE.

Ann Allergy Asthma Immunol. 2010 Jun;104(6):523-9. doi: 10.1016/j.anai.2010.04.012.

PMID:
20568386
16.

Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study.

McMillan CV, Speight J, Relan A, Bellizzi L, Haase G, Cicardi M.

Patient. 2012;5(2):113-26. doi: 10.2165/11597490-000000000-00000.

PMID:
22462765
17.

Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies.

Wahn V, Aberer W, Eberl W, Faßhauer M, Kühne T, Kurnik K, Magerl M, Meyer-Olson D, Martinez-Saguer I, Späth P, Staubach-Renz P, Kreuz W.

Eur J Pediatr. 2012 Sep;171(9):1339-48. doi: 10.1007/s00431-012-1726-4. Epub 2012 Apr 29.

18.

Ecallantide for the treatment of hereditary angiodema in adults.

Lunn M, Banta E.

Clin Med Insights Cardiol. 2011;5:49-54. doi: 10.4137/CMC.S4434. Epub 2011 May 17.

19.

Efficacy assessments in randomized controlled studies of acute therapy for hereditary angioedema.

Caballero T.

J Clin Immunol. 2012 Dec;32(6):1204-12. doi: 10.1007/s10875-012-9734-8. Epub 2012 Jul 15. Review.

PMID:
22797816
20.

Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.

Zanichelli A, Mansi M, Periti G, Cicardi M.

Expert Rev Clin Immunol. 2013 May;9(5):477-88. doi: 10.1586/eci.13.22. Review.

PMID:
23634741

Supplemental Content

Support Center